Re: ALN-CC5
"I've learned to be wary when management starts to say that the main value of an asset will be in combos. I'm pretty certain this means the single agent efficacy is not on par with Soliris."
Too early to make that kind of conclusion without looking at the data. Soliris has reported reduction in LDH anywhere from 40% to 90%. What if ALN-CC5 reports 80% reduction in LDH but the combo therapy of ALN-CC5 and Soliris achieves 95% reduction in LDH? Wouldn't then the combo therapy better than the mono therapy? I think any therapy that brings maximum benefits to the patient is going to be the winner. Looking forward to more data on June 11.